Blue Owl Capital Holdings LP has made a substantial investment in KalVista Pharmaceuticals, Inc., acquiring a new position valued at approximately $1.52 million. The institutional investor purchased 125,000 shares of the specialty pharmaceutical company during the third quarter of 2023, as reported by HoldingsChannel.com.
This significant investment comes as hedge funds and other institutional investors have also adjusted their positions in KalVista. For instance, The Manufacturers Life Insurance Company increased its stake by 5.9% during the second quarter, now holding 14,626 shares valued at $165,000 after acquiring an additional 818 shares. Similarly, BNP Paribas Financial Markets raised its holdings by 47.0%, now owning 4,041 shares worth $46,000 following a purchase of 1,292 shares.
Other notable changes include Rhumbline Advisers, which increased its position by 2.8%, and The Police & Firemen’s Retirement System of New Jersey, which lifted its stake by 26.8%. The latter now owns 9,756 shares valued at $110,000 after acquiring an additional 2,061 shares.
Insider Transactions and Market Performance
In related developments, insider trading activity has been notable. Brian Piekos, Chief Financial Officer of KalVista, sold 1,767 shares on February 23, 2024, at an average price of $15.57, totaling $27,512.19. Following this transaction, Piekos holds 13,762 shares valued at approximately $214,274.34, marking an 11.38% decrease in his position.
Another insider, Paul K. Audhya, also sold shares on the same day, offloading 5,354 shares for a total of $83,361.78. After this sale, Audhya retains 138,983 shares, valued at $2,163,965.31, representing a 3.71% decrease in his holdings. Over the last three months, insiders have collectively sold 33,979 shares worth $535,091, with insiders owning 4.30% of the company’s stock.
KalVista Pharmaceuticals’ shares opened at $16.23 on Friday, reflecting a 0.1% increase. The company has a market capitalization of $820.43 million, a price-to-earnings ratio of -4.11, and a beta of -0.35. Its 52-week low stands at $9.23, while the 52-week high reaches $19.00.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals is a clinical-stage biotechnology firm dedicated to developing small-molecule protease inhibitors aimed at orphan and specialty disease indications. The company focuses on the selective inhibition of plasma kallikrein, a serine protease associated with conditions characterized by vascular leak, edema, and inflammation. Its leading programs include an oral plasma kallikrein inhibitor currently in clinical trials for treating acute attacks of hereditary angioedema (HAE) and an intravitreal kallikrein inhibitor under evaluation for diabetic macular edema.
For those interested in tracking further developments, additional insights on hedge fund holdings and insider transactions related to KalVista Pharmaceuticals can be found at HoldingsChannel.com.
